Obesity

Core Summary A new GLP-1 micro-implant is emerging as the latest breakthrough in weight loss. This implant can continuously release GLP-1 medications, helping patients maintain weight loss long-term. Compared to daily or weekly injections, the implant provides more stable drug release and may solve the problem of weight regain after stopping medication. This innovation could transform the obesity treatment landscape. Event Details According to CNBC reports, this new GLP-1 micro-implant represents the latest advancement in weight loss medication. GLP-1 drugs (such as semaglutide and tirzepatide) have achieved significant results in weight loss in recent years, but patients face the major challenge of weight regain after stopping medication. ...

CVS Restores Coverage for Eli Lilly’s Weight-Loss Drug Zepbound CVS Health, one of America’s largest pharmacy benefit managers, announced it will once again cover Eli Lilly’s weight-loss medication Zepbound (tirzepatide), marking a significant shift in obesity treatment insurance policy in the United States. Zepbound, a GLP-1/GIP dual receptor agonist, has demonstrated remarkable weight-loss results in clinical trials, with patients averaging over 15% body weight reduction within a year. Some participants achieved weight loss exceeding 20%. The drug was initially approved by the FDA for obesity treatment in 2023. ...